News

Articles

Samsung will offer large-scale commercial manufacturing for drug substance and drug products to support AstraZeneca’s biologics therapeutics capabilities in the Asia-Pacific region.

AstraZeneca and Samsung Biologics to Enter into Long-Term Supply Agreement for Up to $545.6 Million

Valneva will supply the UK government with an initial 60 million doses of the vaccine in the second half of 2021, if successful, and will provide more doses thereafter. 

Valneva Enters into $1.6-Billion Partnership with UK Government for COVID-19 Vaccine

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

The White House issued an executive order Sunday, Sept. 13, 2020 implementing a policy to link payments for medicines provided through Medicare to prices charged in other industrial countries. 

Trump Escalates Drug Pricing War

The acquisition will give Gilead access to an anti-cancer antibody drug conjugate in clinical development for treating breast and bladder cancers. 

Gilead to Acquire Immunomedics for $21 Billion

In an opinion article, FDA leaders commit to applying “the best science” to approval decisions.

Career FDA Leaders Say Science Is Agency’s Guide

As public confidence in the drug development process waivers, leading vaccine developers promise to adhere to scientific and regulatory principles.

Vaccine Developers Pledge to Stand with Science

The acquisition will expand Nestlé’s portfolio with access to Aimmune’s Palforzia, the first and only FDA-approved treatment to help reduce the frequency and severity of allergic reactions to peanuts in children.

Nestlé Health Science to Acquire Aimmune Therapeutics for $2.6 Billion

The transaction will give Ionis access to Akcea's pipeline and commercial products, as well as its cash on hand of approximately $390 million.

Ionis to Acquire Akcea Common Stock for $500 Million

FDA issued an emergency use authorization for COVID-19 convalescent plasma treatments following a report on NIH concerns about insufficient studies and data. 

FDA Issues EUA for COVID-19 Convalescent Plasma 

BioMarin received the complete response letter for valoctocogene roxaparvovec, its gene therapy intended for treating severe hemophilia A.

Top News